Evidence map›Paper›PMID 37108737›Full record

ArticleInternational journal of molecular sciences2023

Simvastatin Reduces Doxorubicin-Induced Cardiotoxicity: Effects beyond Its Antioxidant Activity.

Michela Pecoraro, Stefania Marzocco, Raffaella Belvedere, Antonello Petrella, Silvia Franceschelli, Ada Popolo

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease.International journal of molecular sciences · 2024
    Review
  9. Article
  10. Review
  11. Cardioprotective Effect of Hydroalcohol Extract of Andaliman (Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Michela PecoraroDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.
Stefania MarzoccoDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.ORCID 0000-0003-2333-1630
Raffaella BelvedereDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.ORCID 0000-0002-5036-7869
Antonello PetrellaDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.ORCID 0000-0002-6945-5295
Silvia FranceschelliDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.ORCID 0000-0001-7412-7918
Ada PopoloDepartment of Pharmacy, University of Salerno, 84084 Fisciano, SA, Italy.ORCID 0000-0002-9843-8443
University of Salerno · IT

Funding

University of Salerno FARB 2021 ORSA212922
6 · The paper itself

Abstract

This study aimed to evaluate if Simvastatin can reduce, and/or prevent, Doxorubicin (Doxo)-induced cardiotoxicity. H9c2 cells were treated with Simvastatin (10 µM) for 4 h and then Doxo (1 µM) was added, and the effects on oxidative stress, calcium homeostasis, and apoptosis were evaluated after 20 h. Furthermore, we evaluated the effects of Simvastatin and Doxo co-treatment on Connexin 43 (Cx43) expression and localization, since this transmembrane protein forming gap junctions is widely involved in cardioprotection. Cytofluorimetric analysis showed that Simvastatin co-treatment significantly reduced Doxo-induced cytosolic and mitochondrial ROS overproduction, apoptosis, and cytochrome c release. Spectrofluorimetric analysis performed by means of Fura2 showed that Simvastatin co-treatment reduced calcium levels stored in mitochondria and restored cytosolic calcium storage. Western blot, immunofluorescence, and cytofluorimetric analyses showed that Simvastatin co-treatment significantly reduced Doxo-induced mitochondrial Cx43 over-expression and significantly increased the membrane levels of Cx43 phosphorylated on Ser368. We hypothesized that the reduced expression of mitochondrial Cx43 could justify the reduced levels of calcium stored in mitochondria and the consequent induction of apoptosis observed in Simvastatin co-treated cells. Moreover, the increased membrane levels of Cx43 phosphorylated on Ser368, which is responsible for the closed conformational state of the gap junction, let us to hypothesize that Simvastatin leads to cell-to-cell communication interruption to block the propagation of Doxo-induced harmful stimuli. Based on these results, we can conclude that Simvastatin could be a good adjuvant in Doxo anticancer therapy. Indeed, we confirmed its antioxidant and antiapoptotic activity, and, above all, we highlighted that Simvastatin interferes with expression and cellular localization of Cx43 that is widely involved in cardioprotection.

Indexed as

AntioxidantsConnexin 43ApoptosisCalciumCardiotoxicityDoxorubicinHumansMyocytes, CardiacSimvastatinAntioxidantsCalciumConnexin 43DoxorubicinSimvastatincardiotoxicityConnexin 43Doxorubicinoxidative stressSimvastatin

Identifiers

PMID37108737
PMCPMC10141713
OpenAlexW4366597464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.